Sterile Compounding (503A / 503B)
Preparing patient-specific or limited-batch sterile medications outside conventional manufacturing — bridging the gap when a commercial product doesn’t fit the patient or the supply, with beyond-use dating and environmental control standing between the preparation and a patient.
Sterile medications made to fit a patient — or a shortage.
Sterile compounding is the preparation of patient-specific or limited-batch sterile medications — admixtures, dilutions, repackaged injectables — outside conventional manufacturing. It’s done by a pharmacy under 503A, per-prescription, or by an outsourcing facility under 503B, in batches under cGMP. It bridges the gap when a commercially available sterile drug doesn’t fit the patient or the supply need.
The two lanes matter. 503A is per-prescription and pharmacy-scale under USP <797>; 503B is batch manufacturing under cGMP that can make without patient-specific prescriptions and ship across states — a meaningfully higher bar, and the line between them is where a lot goes wrong.
The levers are the cleanroom and primary-engineering-control environment, aseptic technique and competency, beyond-use dating, and — for 503B — cGMP batch controls. As with any sterile process, the work happens in an ISO 5 hood or isolator inside a controlled cleanroom, and the assurance lives in the monitoring and competency around it.
Components are verified and beyond-use dating planned, aseptic manipulations combine or dilute or repackage the sterile product, finished preparations are labeled with a beyond-use date and storage, and 503B layers on cGMP, stability, and batch release.
Process flow
Components verified; beyond-use dating planned
Compounding performed in an ISO 5 primary engineering control within a controlled cleanroom
Aseptic manipulations to combine, dilute, or repackage the sterile product
Finished preparations labeled with beyond-use date and storage
Environmental monitoring, garbing, and competency throughout; 503B adds cGMP, stability, and batch release
Sterile compounded preparations for dispensing or distribution
Sterile, often injectable — made outside full manufacturing controls.
These are sterile products, frequently injectable, prepared outside the full controls of a manufacturer — historically a source of serious contamination harm. Beyond-use dating, environmental control, and, for 503B, cGMP and stability data are what stand between the preparation and the patient who receives it.
The most consequential failure isn’t always a contamination event — it’s a lane violation. A 503A operation that behaves like a manufacturer, batching for office use without prescriptions, is operating beyond its regulatory lane and outside the controls that scale demands. The discipline is beyond-use dates justified by stability or USP, real environmental and competency programs, honest operation within the 503A/503B boundary, manufacturing-grade cGMP and release for 503B, and <800> containment for hazardous drugs.
503A operates per-prescription under USP <797>; 503B under cGMP (21 CFR 211) with stability and release. USP <800> governs hazardous drugs.
Why compounding, and which lane — and what each trades.
Compounding fills a gap a manufactured product can’t. Knowing the choices behind it tells you which controls apply.
Commercial manufactured product
An FDA-approved manufactured product is the default and carries full approval.
503A vs. 503B
503A is per-prescription, pharmacy-scale, under USP <797>.
Aseptic manufacturing
Full aseptic manufacturing shares the sterility logic at larger scale.
The gaps a reviewer looks for on a sterile-compounding operation.
None of these are exotic. They’re the quiet places a compounding operation drifts out of control — recognizable the moment you’ve worked a cleanroom.
Beyond-use dates are assigned beyond what stability or USP supports.
Environmental monitoring, garbing, and media-fill/competency programs are weak.
503A volume or batching looks like manufacturing without 503B registration.
For 503B, cGMP, stability, and endotoxin/sterility release aren’t at manufacturing standard.
Hazardous-drug (<800>) containment is absent where required.
Component sourcing and traceability for sterile ingredients are loose.
Six things to check against your own records.
Not an audit — a read you can run yourself before anyone else does. Pull the records and walk them.
Ask how beyond-use dates are justified — stability data, or default limits?
Review environmental monitoring, garbing, and personnel competency/media-fill records.
For 503A, check whether batching without prescriptions is happening (a 503B activity).
For 503B, confirm cGMP batch records, stability, and sterility/endotoxin release.
Look at <800> containment for hazardous drugs.
Trace sterile component sourcing and qualification.
The same discipline, across different needs.
The preparation and lane change — the discipline never does: justify the dating, hold the environment, stay in your lane.
Patient-specific admixtures
Per-prescription IV admixtures, dilutions, and tailored sterile preparations under USP <797> for an individual patient.
Outsourced batch preparations
Batch sterile preparations made under cGMP for office and hospital use — manufacturing-grade controls without a per-patient prescription.
Shortage & repackaging
Repackaged injectables and shortage-gap preparations, where component sourcing and beyond-use dating carry the risk.
Hazardous-drug compounding
Sterile compounding of hazardous drugs under USP <800>, where containment protects personnel as well as the product.
Know the process. Now decide how far to take it.
These doors connect to this technology. None outranks another — pick the one that fits where you are.
Training
A course on sterile compounding and the standard it has to meet — so your team understands beyond-use dating, the 503A/503B line, and <797>/<800> before they run or review the step.
Browse trainingService
Send us one record from this step — a beyond-use-date justification, an environmental-monitoring log, a competency record — and get a written read on whether it holds up, and what would close the gap.
See servicesAssessment
Your held documents for this step graded against the standard’s rubric — a readiness matrix of what passes, what’s a gap, and what’s at risk.
See assessmentsProgram
A complete, buy-and-go document system for the standard this step has to satisfy — download it all, or follow the guided build. No meetings required.
Explore programsConsulting
When the productized options don’t fit — a scoped, senior review of your situation and a written path, by inquiry.
Start a conversation